New antibody combo takes on Hard-to-Treat myeloma
NCT ID NCT07210047
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new antibody drug called HuL001, given together with two standard myeloma drugs (lenalidomide and dexamethasone), in 21 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if the combination is safe and can shrink or control the cancer. Participants receive HuL001 injections every two weeks, take lenalidomide for 21 days each month, and take dexamethasone weekly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HuL001 (an antibody) combined with lenalidomide and dexamethasone
- What this could lead to
- If this works, it could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial with only 21 participants, so results may not apply to everyone. The combination may cause side effects or fail to control the disease long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Far Eastern Memorial Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take on incurable blood cancer
- New CAR T-Cell therapy targets Hard-to-Treat myeloma
- New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
- Why do blood cancer patients skip home care? new study aims to find out.
- Could a simple shot replace hospital stays for myeloma patients?
- Engineered immune cells take on Hard-to-Treat myeloma